Patients should monitor for signs of volume depletion, including decreased urine output, dizziness, or excessive thirst
You can read the abstract of this article at Poudel SB, Frikha-Benayed D, Ruff RR, Yildirim G, Dixit M, Korstanje R, Robinson L, Miller RA, Harrison DE, Strong JR, Schaffler MB, Yakar S
Retatrutide is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) and should only be used under specialist supervision or within a formal clinical trial
Novo Nordisk had not been able to manufacture enough Wegovy to meet demands, leaving the drug in short supply throughout much of 2023 and 2024
By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify
She will review all appropriate options with you during your initial consultation